Trial Profile
A Pilot Study of IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With neoADjuvant Avelumab, Palbociclib, and Endocrine Therapy: The ImmunoADAPT Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Palbociclib (Primary) ; Goserelin; Letrozole; Leuprorelin; Tamoxifen
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms ImmunoADAPT
- 26 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 26 Mar 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Jul 2024.
- 09 Dec 2023 Primary endpoint has not been met. (Clinical Complete Response), as per Results presented at the 46th Annual San Antonio Breast Cancer Symposium